痛风患者血清尿酸与痛风发作的关联及替代标志物证据:两项随机对照试验的二次分析
该研究基于英国诺丁汉和新西兰两项随机试验的个体患者数据,分析达标血清尿酸(<6 mg/dL)与后续12个月痛风发作的因果关联。共识别343例血清尿酸应答者和245例非应答者,应答者痛风发作比例和每月平均发作次数均显著低于非应答者。结果支持在痛风管理中采用达标治疗策略。
要点
- 血清尿酸应答者(平均<6 mg/dL)后续12个月痛风发作比例27%,非应答者64%。
- 应答者每月平均发作次数较非应答者显著降低,校正平均差-1.41(95%CI -1.77至-1.04)。
- 该关联独立于原始随机治疗分组,支持达标治疗血清尿酸策略。
核心结论
- 达到平均血清尿酸浓度低于6 mg/dL与痛风患者后续12个月无痛风发作及发作次数减少相关。
- 这些结果支持在痛风管理中采用达标治疗血清尿酸策略。
研究设计与样本
- 对英国诺丁汉和新西兰两项降尿酸治疗随机试验的个体患者数据进行二次分析。
- 纳入新西兰研究中随机分配至立即剂量递增的参与者以及诺丁汉研究的所有参与者(护士主导痛风护理组和全科医生主导常规护理组)。
- 基于基线后6、9和12个月数据,平均血清尿酸浓度低于6 mg/dL(0.36 mmol/L)者定义为血清尿酸应答者。
- 主要结局为基线后12至24个月期间至少有一次痛风发作的参与者比例,次要结局为每参与者每月平均发作次数。
- 校正逻辑回归模型纳入基线血清尿酸、既往发作史(研究入组前一年)、基线痛风石存在情况以及诺丁汉数据集的原始随机分组作为协变量。
主要发现
- 共识别343例血清尿酸应答者和245例血清尿酸非应答者。
- 12至24个月期间,血清尿酸应答者中至少有一次痛风发作的比例显著低于非应答者(91/343[27%] vs 156/245[64%];校正OR 0.29[95%CI 0.17至0.51],p<0.0001)。
- 12至24个月期间,血清尿酸应答者每参与者每月平均发作次数显著低于非应答者(校正平均差-1.41[95%CI -1.77至-1.04],p<0.0001)。
- 该关联独立于原始随机治疗分配。
关键数值与推荐
- 血清尿酸应答定义为平均血清尿酸浓度低于6 mg/dL(0.36 mmol/L),基于基线后6、9和12个月数据。
- 主要结局为基线后12至24个月期间至少有一次痛风发作的参与者比例。
- 次要结局为基线后12至24个月期间每参与者每月平均发作次数。
临床怎么用
- 原文结论支持在痛风管理中采用达标治疗血清尿酸策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of serum urate as a treatment target and outcome measure has become controversial in view of the 2017 American College of Physicians guidelines, which advocated a treat-to-symptom rather than a treat-to-target serum urate approach to gout management. The relevance of serum urate as a treatment target measure implies that achievement of target serum urate is causally associated with improvement in patient-important outcomes such as reduction in the number of gout flares. The aim of this study was to assess the causal relationship between achieving target serum urate and the occurrence of gout flares. METHODS: We analysed individual patient-level data from two randomised trials on urate-lowering therapies in people with gout conducted in Nottingham, UK, and New Zealand. We included participants randomly assigned to immediate dose escalation in the New Zealand study and all participants in the Nottingham study (a nurse-led gout care group and a general practitioner-led usual care group). Individuals who on average achieved a serum urate concentration less than 6 mg/dL (0·36 mmol/L) based on data at 6, 9, and 12 months post-baseline were defined as serum urate responders. The primary outcome was the proportion of participants having at least one gout flare, and the secondary outcome was the mean number of flares per participant per month, from 12 to 24 months after baseline, compared between serum urate responders and non-responders. In adjusted logistic regression models, serum urate at baseline, previous flare history (in the year preceding study entry), presence of tophi at baseline, and, for the Nottingham dataset, the original randomisation group, were included as covariates. The Nottingham study was registered with ClinicalTrials.gov, NCT01477346. The New Zealand study was registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000845932. FINDINGS: From the combined individual data from both trials, we identified 343 serum urate responders and 245 serum urate non-responders. Significantly fewer serum urate responders had a gout flare than did serum urate non-responders between 12 and 24 months (91 [27%] of 343 vs 156 [64%] of 245; adjusted odds ratio [OR] 0·29 [95% CI 0·17 to 0·51], p<0·0001). The mean number of flares per participant per month between 12 and 24 months was significantly lower in serum urate responders than in serum urate non-responders (adjusted mean difference -1·41 [95% CI -1·77 to -1·04], p<0·0001). This association was independent of the original randomised treatment allocation. INTERPRETATION: Achieving an average serum urate concentration less than 6 mg/dL is associated with an absence of gout flares and a reduction in the number of flares in the subsequent 12 months in people with gout. These results support a treat-to-target serum urate approach in the management of gout. FUNDING: None.
引用
- Stamp LK, Frampton C, Morillon MB, et al. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 2021. PMID: 38288731. doi:10.1016/S2665-9913(21)00319-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。